SeekingAlpha · Jul 17, 2026
Orexo AB (publ) 2026 Q2 - Results - Earnings Call Presentation
2026-07-17. The following slide deck was published by Orexo AB (publ) in conjunction with their 2026 Q2 earnings call.
OTC · ORXOY
Healthcare · Drug Manufacturers - Specialty & Generic
$1.77
Up+$0.00 (+0.00%)
Updated Aug 17, 2026, 8:33 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 1 trading sessions · Daily adjusted prices
ORXOY closed at $1.77 after 1 trading sessions, up 0.00% for the selected period.
No results
At least two price observations are needed to draw this chart.
The latest Smart Investors Daily articles mentioning ORXOY.
ORXOY research
Company profile and research snapshot.
OREXO AB SP/ADR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 18, 2026 | RX SECURITIES | Buy | — |
| Feb 5, 2026 | RX SECURITIES | Buy | — |
| Jan 5, 2026 | RX SECURITIES | Buy | — |
| Jan 4, 2026 | RX SECURITIES | Buy | — |
| Oct 23, 2025 | RX SECURITIES | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Jul 17, 2026
2026-07-17. The following slide deck was published by Orexo AB (publ) in conjunction with their 2026 Q2 earnings call.
SeekingAlpha · Jul 16, 2026
Orexo AB (publ) (ORXOY) Q2 2026 Earnings Call July 16, 2026 8:00 AM EDTCompany ParticipantsNikolaj Sørensen - President & CEOFrederik Jarrsten -...
SeekingAlpha · Feb 5, 2026
2026-02-05. The following slide deck was published by Orexo AB (publ) in conjunction with their 2025 Q4 earnings call.
SeekingAlpha · Feb 5, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning ORXOY.